Axonics Modulation Technologies, Inc. (AXNX) News
Filter AXNX News Items
AXNX News Results
|Loading, please wait...|
AXNX News Highlights
- 500 - Internal server error
- Over the past 6 days, the trend for AXNX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AXNX are INS and CE.
Latest AXNX News From Around the Web
Below are the latest news stories about Axonics Inc that investors may wish to consider to help them evaluate AXNX as an investment opportunity.
Axonics (AXNX) announces European CE Mark approval of its second generation Axonics r-SNM implantable neurostimulator ((INS)) and wireless patient remote control with SmartMRI technology. Axonics previously received FDA approval for this INS and remote control during 2020. This version reduces how frequently a patient needs to recharge their sacral neuromodulation device...
Axonics (AXNX) has priced its public offering of 3.5M common shares at $50.00/share, for expected gross proceeds of $175M.Underwriters' over-allotment is an additional 525K shares. Net proceeds will be used to repay outstanding indebtedness, for commercialization purpose, R&D activities, working capital and general corporate purposes.Closing date is May 14.Shares down 4.6% after-hours.Previously...